AstraZeneca PLC (LON:AZN) price target maintained at 4,900.00GBX, reported earlier today by JP Morgan Cazenove
- Updated: September 18, 2016
JP Morgan Cazenove held the estimated target of AstraZeneca PLC (LON:AZN) at 4,900GBX, reporting a possible downside of -0.05%.
Yesterday AstraZeneca PLC (LON:AZN) traded 2.02% higher at 5,159.50GBX. AstraZeneca PLC’s 50-day average is 5,017.86GBX and its two hundred day moving average is 4,330.50GBX. The last stock price close is up 17.65% from the 200-day average, compared with the S&P 500 Index which has fallen -0.01% over the same period. 4,505,466 shares of AstraZeneca PLC traded hands, up from ann average volume of 2,849,440.
See Graph Below:
With a total market value of 0.0 GBX, AstraZeneca PLC has a one-year low of 3,680.00GBX and a one-year high of 5,505.00GBX with a price-earnings ratio of 29.
In addition to JP Morgan Cazenove reporting it’s stock price target, a total of 29 analysts have issued a ratings update on the company. The 12-month target stock price is 61.96GBX with four firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, two firms rating the stock to underperform, and lastly one analystrating the stock as sell.
More About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, and among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.